Mitchell Mutz, Ph.D.
Mitchell Mutz, PhD, is an Entrepreneur Partner of Vivo Capital. He is a successful biotech serial entrepreneur, venture investor, and inventor with over 20 years experience in starting and investing in biotechnology companies. Mitchell was previously Senior Investment Director of the Roche Venture Fund where he led new investments in and served on the boards of Pandion Therapeutics (acquired by Merck), Good Therapeutics, Jasper Therapeutics, EnLiven Therapeutics (observer) and Kumquat Biosciences (observer).
Previously, Mitchell was a co-founder, president, chief scientific officer, and board member of Amplyx Pharmaceuticals, Inc., a biotherapeutics company, acquired by Pfizer. Mitchell was also on the founding team and the Principal Scientist of Labcyte, a tools company he helped grow from inception and was later acquired by Beckman-Coulter, Inc.
Mitchell earned a Ph.D. in Chemistry from the University of Rochester, a Diploma in Orchestral Studies from the University of London, and a B.A. in Chemistry with high honors from Oberlin College.